 Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mgkg, generally consistent with prior 10 and 20 mgkg results Among 3 mgkg VRDN-001 treated patients, 67 were proptosis responders, 56 were overall responders, 67 achieved a Clinical Activity Score CAS of 0 or 1, and ... The post Viridian Announces Positive Data from Ongoing Phase 12 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease TED appeared first on ForexTV... 